摘要 :
In this article, the authors review the basic principles of cancer chemotherapy and provide an overview of each of the general classes of chemotherapeutic agents with a target audience of interventional radiologists in mind. Speci...
展开
In this article, the authors review the basic principles of cancer chemotherapy and provide an overview of each of the general classes of chemotherapeutic agents with a target audience of interventional radiologists in mind. Special attention is paid to agents used in regional chemotherapy as well as agents commonly included in systemic chemotherapeutic regimens for patients who also require regional chemotherapy.
收起
摘要 :
Objectives: Prescribing, dosing and delivering chemotherapy to the cancer patients is a complex, highly specialized and time consuming process, requiring a specialized team (medical oncology clinician or veterinarian, nurse, pharm...
展开
Objectives: Prescribing, dosing and delivering chemotherapy to the cancer patients is a complex, highly specialized and time consuming process, requiring a specialized team (medical oncology clinician or veterinarian, nurse, pharmacist). Our aim was to create a software that fills the gap between medical doctors, pharmacists and nurses and consequently speeds up the calculation, dosing and preparation of chemotherapy and biological (targeted) therapy in medical oncology. Dedicated versions for human and veterinary medicine are available.
收起
摘要 :
Background: Targeting chemotherapeutic agents to the tumor tissues and achieving accumulation with ideal release behavior for desired therapy requires an ideal treatment strategy to inhibit division of rapid growing cancerous cell...
展开
Background: Targeting chemotherapeutic agents to the tumor tissues and achieving accumulation with ideal release behavior for desired therapy requires an ideal treatment strategy to inhibit division of rapid growing cancerous cells and as an outcome improve patient's quality of life. However, majority of the available anticancer therapies are well known for their systemic toxicities and multidrug resistance.
收起
摘要 :
Dieser Beitrag liefert einen Überblick über aktuelle Standards in der Systemtherapie des Urothelkarzinoms sowie neueste Studienergebnisse aus Publikationen und internationalen Kongressen des Jahres 2011. Sowohl Studien zur neoad...
展开
Dieser Beitrag liefert einen Überblick über aktuelle Standards in der Systemtherapie des Urothelkarzinoms sowie neueste Studienergebnisse aus Publikationen und internationalen Kongressen des Jahres 2011. Sowohl Studien zur neoadjuvanten und adjuvanten systemischen Chemotherapie des resektablen Harnblasenkarzinoms als auch zur systemischen Behandlung des metastasierten Urothelkarzinoms werden zusammengefasst.
收起
摘要 :
Über die Wirksamkeit systemischer Chemotherapeutika zur Behandlung des Urothelkarzinoms wird seit mehr als 30 Jahren berichtet. Mit der Kombination verschiedener Substanzen wurde ab Mitte der 80er Jahre eine potenzielle Heilbarke...
展开
Über die Wirksamkeit systemischer Chemotherapeutika zur Behandlung des Urothelkarzinoms wird seit mehr als 30 Jahren berichtet. Mit der Kombination verschiedener Substanzen wurde ab Mitte der 80er Jahre eine potenzielle Heilbarkeit auch fortgeschrittener Erkrankungsstadien in dieser Tumorentität postuliert, was seither in eine Serie von Phase-III-Studien zur systemischen Kombinationstherapie in dieser Entität mündete. Dieser Beitrag stellt die Ergebnisse aus den Indikationsbereichen der palliativen systemischen Chemotherapie des fortgeschrittenen metastasierten Urothelkarzinoms sowie der neoadjuvanten und adjuvanten systemischen Kombinationschemotherapie des muskelinvasiven bzw. lokal fortgeschrittenen resektablen Harnblasenkarzinoms zusammen.
收起
摘要 :
Dieser Beitrag stellt die Ergebnisse aktueller Studien zur systemischen Chemotherapie des fortgeschrittenen/metastasierten Urothelkarzinoms so wie der neoadjuvanten und adjuvanten systemischen Kombinationschemotherapie des resekta...
展开
Dieser Beitrag stellt die Ergebnisse aktueller Studien zur systemischen Chemotherapie des fortgeschrittenen/metastasierten Urothelkarzinoms so wie der neoadjuvanten und adjuvanten systemischen Kombinationschemotherapie des resektablen Harnblasenkarzinoms zusammen. Während über lange Zeit die Therapie mit konventionellen Chemotherapeutika dominierte, sind in den letzten Jahren zunehmend Daten zur Behandlung mit zielgerichteten molekularen Substanzen veröffentlicht worden. In Zukunft wird wie in anderen Tumorentitäten das molekulare „Profiling“ von Patienten zur individualisierten Therapieplanung zu erwarten sein.
收起
摘要 :
As the use of oral chemotherapy continues to rise, new approaches are needed to ensure patient safety. To help address this issue, the American Society of Clinical Oncology/Oncology Nursing Society (ONS) Chemotherapy Administratio...
展开
As the use of oral chemotherapy continues to rise, new approaches are needed to ensure patient safety. To help address this issue, the American Society of Clinical Oncology/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards were expanded in 2013 to include additional measures addressing oral anticancer drugs (OACs). Because minimal data assessing the application of these standards exist, ONS conducted an independent survey of oncology nurses to evaluate the application of these standards in practice as they relate to several areas of OAC use: assessment, consent, patient education, drug verification, and monitoring. The data revealed that, although the standards are followed in many settings, a large number of settings do not have processes in place to support safety standards and ensure patient safety when administering OACs. Information gained in this informal survey can be used to guide additional research and educational initiatives.
收起
摘要 :
Purpose: The published data on ocular survival following intravenous chemotherapy of retinoblastoma (RB) seems to be skewed by evolving practice patterns induced by use of intravitreal chemotherapy (iVitc). We aimed to explore pot...
展开
Purpose: The published data on ocular survival following intravenous chemotherapy of retinoblastoma (RB) seems to be skewed by evolving practice patterns induced by use of intravitreal chemotherapy (iVitc). We aimed to explore potential role of iVitc for vitreous seeding for patients treated with intravenous chemotherapy (IVC). Methods: A literature search was performed to identify cases of RB treated with primary IVC prior to advent of iVitc by various search engines (PubMed, Medline, and Google) from 1992 to 2018. Studies were excluded if number of cases were less than 40 or lacked data related to type of recurrence and its treatment. Rates and patterns of recurrence and its management were categorized. Results: Out of 15 studies identified, only 10 studies (797 eyes) met the inclusion criteria. The mean age at presentation was 15.3 months (range 0-192.8 months). Unilateral cases represented 25% of the cohort. The ocular survival rate with primary IVC was 63% (500/797 eyes). Of the 297 eyes (37%) that failed IVC therapy, additional 99 eyes could be salvaged with EBRT (599/797 eyes, 75%). Remaining 198 eyes were enucleated (198/797 eyes 25%). K-M survival analysis could not be done due lack of sufficient data. Recurrences that occurred (mean 12.2 months) after completion of primary IVC included relapse of retinal tumor (143 eyes [48%]), vitreous seeding (73 eyes [25%]), subretinal seeding (49 eyes [16%]), or any combination (103 eyes [35%]). Out of 73 eyes with vitreous seeding, additional 66 eyes (90%) would have been salvaged with iVitc, potentially improving ocular survival rates to 71% (500 + 66/797). Conclusions: Evolving practice patterns of RB treatment have unfavorably skewed published ocular survival rates following IVC. With incorporation of iVitc, the ocular survival rates with IVC can be potentially improved to be non-inferior to those achieved with intra-arterial chemotherapy.
收起
原文获取